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Background
Prions, the infectious agents responsible for transmissible spongiform encephalopa-
thies, consist mainly of the misfolded prion protein (PrPSc). The unique mechanism 
of transmission and the appearance of a variant form of Creutzfeldt–Jakob disease, 
which has been linked to consumption of prion-contaminated cattle meat, have 
raised concerns about public health. Evidence suggests that variant Creutzfeldt–
Jakob disease prions circulate in body fluids from people in whom the disease is 
silently incubating.
Methods
To investigate whether PrPSc can be detected in the urine of patients with variant 
Creutzfeldt–Jakob disease, we used the protein misfolding cyclic amplification 
(PMCA) technique to amplify minute quantities of PrPSc, enabling highly sensitive 
detection of the protein. We analyzed urine samples from several patients with vari-
ous transmissible spongiform encephalopathies (variant and sporadic Creutzfeldt–
Jakob disease and genetic forms of prion disease), patients with other degenerative 
or nondegenerative neurologic disorders, and healthy persons.
Results
PrPSc was detectable only in the urine of patients with variant Creutzfeldt–Jakob 
disease and had the typical electrophoretic profile associated with this disease. 
PrPSc was detected in 13 of 14 urine samples obtained from patients with variant 
Creutzfeldt–Jakob disease and in none of the 224 urine samples obtained from 
patients with other neurologic diseases and from healthy controls, resulting in an 
estimated sensitivity of 92.9% (95% confidence interval [CI], 66.1 to 99.8) and a 
specificity of 100.0% (95% CI, 98.4 to 100.0). The PrPSc concentration in urine 
calculated by means of quantitative PMCA was estimated at 1×10−16 g per milliliter, 
or 3×10−21 mol per milliliter, which extrapolates to approximately 40 to 100 oligo-
meric particles of PrPSc per milliliter of urine.
Conclusions
Urine samples obtained from patients with variant Creutzfeldt–Jakob disease con-
tained minute quantities of PrPSc. (Funded by the National Institutes of Health and 
others.)
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Prion diseases are fatal neurodegen-erative disorders for which no therapy or definitive noninvasive intravital diagnosis 
is available.1 These diseases affect humans and 
animals. Creutzfeldt–Jakob disease in humans 
and scrapie, bovine spongiform encephalopathy, 
and chronic wasting disease in animals are the 
most common forms of transmissible spongiform 
encephalopathies. The infectious agent in trans-
missible spongiform encephalopathies appears 
to be composed exclusively of the misfolded form 
of the prion protein (termed PrPSc), which self-
propagates in the absence of nucleic acid.2,3 PrPSc 
replicates in infected persons by acting as a tem-
plate for the misfolding of the cellular prion pro-
tein (PrPC). When exposed to the infectious agent, 
prions progressively replicate in the host body, 
and by the time clinical symptoms develop, large 
quantities of PrPSc have accumulated in the cen-
tral nervous system. Although the disease is most-
ly confined to the central nervous system, small 
quantities of PrPSc are present in many tissues 
and body fluids even at early presymptomatic 
stages of the disease.1,4,5
It is widely accepted that bovine spongiform 
encephalopathy has been transmitted to humans, 
generating a new disease termed variant 
Creutzfeldt–Jakob disease.6-8 Although the num-
ber of patients with this disease is fairly small 
(228 cases reported as of this writing), it is un-
clear how many people may carry infectious 
material due to a preclinical or subclinical con-
dition. A recent retrospective study of archived 
surgically resected appendixes in the United 
Kingdom estimated that the prevalence of 
 asymptomatic variant Creutzfeldt–Jakob disease 
infection in the U.K. population was approxi-
mately 1 case per 2000 persons; this suggests 
that approximately 30,000 people in the United 
Kingdom might be carriers of potentially infec-
tious variant Creutzfeldt–Jakob disease prions.9 
The potential existence of a large number of 
carriers raises the possibility of horizontal trans-
mission of variant Creutzfeldt–Jakob disease from 
human to human, a course that has already led 
to hundreds of deaths in other human transmis-
sible spongiform encephalopathies.10 Studies in 
animal models have shown that bovine spongi-
form encephalopathy infection often results in 
subclinical or carrier states, which on secondary 
transmission can produce the complete disease 
in a much more efficient way.11-13 This scenario 
is a concern, since cases of variant Creutzfeldt–
Jakob disease have been linked to transfusion of 
blood donated by infected persons at the pre-
clinical stage of the disease.14-16
Noninvasive tests that can detect prions in 
samples of body fluids with high sensitivity and 
specificity could be useful for estimating the 
prevalence of variant Creutzfeldt–Jakob disease 
prion infection, reducing the risk of iatrogenic 
transmission, and facilitating prophylactic treat-
ment of the disease. One of the most promising 
techniques for high-sensitivity detection of PrPSc 
is the protein misfolding cyclic amplification 
(PMCA) assay, which mimics in vitro the prion 
replication process occurring during the patho-
genesis of prion disease.17 PMCA is a cyclic 
process that can detect the equivalent of a single 
oligomeric particle of PrPSc.18 This high level of 
sensitivity has permitted detection of PrPSc in the 
blood and urine of experimentally infected ani-
mals at both the symptomatic19,20 and presymp-
tomatic21 stages of the disease. PMCA has been 
successfully used to detect PrPSc in affected spe-
cies, including humans.22 We investigated wheth-
er PrPSc is present in the urine of patients with 
variant Creutzfeldt–Jakob disease and whether it 
can be detected by means of PMCA. Urine test-
ing is the least invasive type of sampling for 
detection of a disease marker, and urine has 
been shown to carry small quantities of infec-
tious PrPSc in experimental animal models.20,23-26
Me thods
Patients and Study Oversight
We analyzed urine samples obtained from 68 pa-
tients with sporadic Creutzfeldt–Jakob disease 
and 14 patients with variant Creutzfeldt–Jakob 
disease (clinical information about these patients 
is provided in Table S1 in the Supplementary 
Appendix, available with the full text of this article 
at NEJM.org), as well as 4 patients with genetic 
prion diseases, 50 patients with other neurode-
generative disorders (including Alzheimer’s dis-
ease, Parkinson’s disease, frontotemporal demen-
tia, motor neuron disease, and progressive 
supranuclear palsy), 50 patients with nondegen-
erative neurologic disorders (including cerebro-
vascular disease, multiple sclerosis, epilepsy, brain 
tumors, autoimmune encephalitis, meningitis, 
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myeloradiculopathy, and peripheral neuropathy), 
and 52 healthy persons. The diagnosis of human 
transmissible spongiform encephalopathy in all 
patients (except for 1 patient with variant 
Creutzfeldt–Jakob disease) was pathologically 
confirmed on autopsy or by means of biopsy of 
brain tissue, lymphoid tissue, or both. The diag-
nosis of the other neurologic diseases was estab-
lished by means of clinical examination, as well 
as imaging and laboratory tests, when available. 
All patients and controls included in the study 
were homozygous for methionine at codon 129 
of the gene encoding prion protein (PRNP) (PRNP 
genotyping is described in the Supplementary 
Appendix). Urine was collected at various times 
during the symptomatic period of the diseases 
and kept frozen at −80°C until analysis.
The methods of urine collection and genetic 
analysis were approved by the institutional re-
view boards at the authors’ study centers, and all 
study participants provided written informed 
consent. The sponsors had no role in the study 
design, data collection and analysis, preparation 
of the manuscript, or decision to submit it for 
publication.
Urine Processing
To attempt direct detection of PrPSc by means of 
Western blotting, 1 ml of each urine sample was 
concentrated by means of centrifugation at high 
speed (100,000×g for 1 hour at 4°C). The superna-
tant was discarded, and pellets were washed with 
phosphate-buffered saline. After washing, pellets 
were resuspended in 10 μl of phosphate-buffered 
saline. Samples were subjected to proteinase K di-
gestion and Western blotting, as described below.
For PMCA, urine samples were processed as 
shown in Figure 1. Briefly, 1 ml of each sample 
was subjected to an initial low-speed centrifuga-
tion (5000×g for 20 minutes at 4°C) to precipitate 
debris. The supernatant and pellet fractions were 
both used for PrPSc detection after concentration 
by means of centrifugation, as described in 
Figure 1. For the studies with 10 ml of urine 
samples, a simplified procedure was performed 
in which samples were subjected to a single cen-
trifugation at 100,000×g for 1 hour at 4°C. In 
this way, the materials associated with both de-
bris and supernatant were included in the sample. 
The pellet was resuspended directly in 100 μl of 
PMCA substrate.
PMCA Procedure
PMCA was performed as previously described.22 
As a substrate, we used brain specimens ob-
tained from transgenic mice expressing human 
prion protein with methionine homozygosity at 
PRNP codon 129. Brains were harvested after per-
fusion, and 10% homogenate was prepared in 
conversion buffer (phosphate-buffered saline con-
taining 150 mM sodium chloride and 1% Triton 
X-100) with the addition of protease inhibitors. 
To increase the efficiency of PMCA, 6 mM EDTA 
and 0.05% digitonin were added to the brain 
homogenate.
Urine samples, processed as described above, 
were mixed with 10% brain homogenate (from 
transgenic mice expressing human prion protein) 
in tubes containing three polytetrafluoroethylene 
(Teflon) beads and subjected to 96 cycles of 
PMCA with the use of a microsonicator (model 
Q700, Qsonica). Each cycle consisted of 29 min-
utes 20 seconds of incubation at 37 to 40°C, 
followed by a 40-second pulse of sonication set 
at a potency of 270 to 280 W. After one round of 
96 PMCA cycles, an aliquot of the amplified ma-
terial was diluted by a factor of 10 into fresh 
brain homogenate from transgenic mice and an 
additional round of PMCA cycles was performed. 
To avoid sample cross-contamination between 
rounds, thorough decontamination of instru-
ments and equipment was performed with the 
Figure 1 (facing page). Urine Processing and Protein 
Misfolding Cyclic Amplification (PMCA) Procedure.
One milliliter of urine was first centrifuged at low speed 
to separate debris. The pellet fraction containing cellular 
debris was resuspended in 1 ml of water and subjected 
to high-speed centrifugation (100,000 × g) to precipitate 
misfolded prion protein (PrPSc). The pellet was resus-
pended directly in brain homogenate from transgenic 
mice expressing human prion protein and used as a 
substrate for PMCA. The supernatant fraction from the 
low-speed centrifugation was centrifuged at high speed 
to pellet PrPSc and remove urine compounds that inter-
fere with PMCA. The pellet was resuspended in brain 
homogenate from transgenic mice and used for PMCA 
amplification. The PMCA procedure comprises cycles 
of amplification in which incubation of oligomeric seeds 
with the monomeric prion protein to allow growth of 
the polymers is followed by fragmentation of the aggre-
gates by means of sonication to multiply the number of 
nuclei for prion replication. After 96 PMCA cycles, the 
cellular prion protein (PrPC) substrate is refreshed, and 
samples are subjected to a new round of PMCA cycling.
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use of 2 N sodium hydroxide or 4 M guanidine 
isothiocyanate.
Proteinase K Digestion and Western Blot 
Analysis
Samples were treated with proteinase K (100 μg 
per milliliter) for 1 hour at 37°C with shaking. 
The reaction was stopped with the use of lithium 
dodecyl sulfate sample buffer (NuPAGE, Invitro-
gen), and samples were developed by means of 
Western blotting as previously described.22
R esult s
prpSc detection in urine by western blotting 
and pmca
In a first attempt to detect PrPSc in urine, samples 
obtained from patients with various forms of 
transmissible spongiform encephalopathies, as 
well as from persons with other neurodegenera-
tive diseases and healthy controls, were concen-
trated and analyzed by means of Western blot-
ting after proteinase K digestion. The results 
showed that even after concentration by a factor 
of 100, no protease-resistance prion protein sig-
nal was detectable in any of the samples analyzed 
(Fig. S1A in the Supplementary Appendix). To 
further attempt detection of PrPSc in human 
urine, we used the PMCA technique. First, we op-
timized the method, using samples of urine from 
healthy persons that were supplemented with 
various dilutions of variant Creutzfeldt–Jakob 
disease brain homogenate, ranging from 10−5 to 
10−12. After one and two rounds of 96 PMCA cy-
cles, we could detect human PrPSc at a brain ho-
mogenate dilution of 10−10 and 10−12, respectively 
(Fig. 2A). No PrPSc was detected even after seven 
rounds of PMCA in urine samples that were sup-
plemented with 10% healthy brain homogenate 
(Fig. S1B in the Supplementary Appendix).
prpSc detection in urine of patients  
with variant creutzfeldt–jakob disease
Next, we used PMCA to detect PrPSc in urine sam-
ples obtained from 238 persons (Table 1), includ-
ing 68 patients with sporadic Creutzfeldt–Jakob 
disease, 14 patients with variant Creutzfeldt–
Jakob disease (Table S1 in the Supplementary 
Appendix), 4 patients with genetic forms of trans-
missible spongiform encephalopathies (3 patients 
with the Gerstmann–Sträussler–Scheinker syn-
drome and 1 with familial Creutzfeldt–Jakob dis-
ease), 50 patients with other neurodegenerative 
diseases, 50 patients with nondegenerative neu-
rologic diseases, and 52 healthy persons. All pa-
tients and healthy controls were homozygous for 
methionine at PRNP codon 129.
Figure 2B shows results of some of the sam-
ples analyzed. Among all samples tested in a 
blinded manner, only the one obtained from a 
patient with variant Creutzfeldt–Jakob disease 
(lane 3 in Fig. 2B) was positive for PrPSc, besides 
the positive control sample (lane 9 in Fig. 2B) 
consisting of urine from a healthy control that 
was supplemented with a 10−5 dilution of variant 
Creutzfeldt–Jakob disease brain homogenate. In 
the urine sample obtained from the patient with 
variant Creutzfeldt–Jakob disease, PrPSc was detec-
table both in the debris and in the supernatant 
fraction after precipitation of the debris (Fig. 2B). 
No signal was detected in any of the urine sam-
ples obtained from patients with other forms of 
human transmissible spongiform encephalopa-
thies (i.e., sporadic Creutzfeldt–Jakob disease, 
familial Creutzfeldt–Jakob disease, and the 
Gerstmann–Sträussler–Scheinker syndrome), pa-
tients with other degenerative or nondegenerative 
neurologic disorders, and healthy controls, even 
after seven rounds of PMCA (Fig. 2B and 2C).
Similar results were obtained with the rest of 
the samples analyzed (Fig. 3A). Indeed, a positive 
signal for PrPSc was detected in both the super-
natant and debris fraction for 13 of the 14 urine 
samples obtained from patients with variant 
Creutzfeldt–Jakob disease (Table 1). No signal 
was detected in any of the other samples ana-
lyzed, indicating that, with this technique, PrPSc 
is detectable exclusively in the urine of patients 
with variant Creutzfeldt–Jakob disease. PMCA 
enables PrPSc detection in patients with variant 
Creutzfeldt–Jakob disease with an estimated sen-
sitivity of 93% and an estimated specificity of 
100%, and the positive and negative predictive 
values are close to 100% (Table 2). To investigate 
whether larger samples of urine from different 
control groups might be positive, we performed 
an experiment using samples of 10 ml of urine 
obtained from 10 patients with sporadic 
Creutzfeldt–Jakob disease, 10 patients with other 
neurodegenerative diseases, and 10 healthy con-
trols. Samples were processed as described 
above, and all material obtained from the 10 ml 
of urine was used for the PMCA assays. As 
shown in Figure 3B, no signal was detected in 
any of these samples.
After proteinase K digestion, the electropho-
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Figure 2. PrPSc Detection in Urine by Means of PMCA.
As shown in Panel A, to optimize PrPSc detection by means of PMCA, 1 ml of urine from healthy persons was supplemented with samples 
of variant Creutzfeldt–Jakob disease brain homogenate at distinct dilutions (10−5 to 10−12). After processing by means of high-speed centrifuga-
tion, samples were subjected to various rounds of 96 PMCA cycles in the presence of 10% brain homogenate from transgenic mice express-
ing human prion protein, which was used as a substrate for PMCA. The PrPSc signal was assessed by means of Western blot analysis after 
proteinase K digestion. NBH refers to the normal (healthy) brain homogenate. As shown in Panel B, urine samples obtained from patients 
with sporadic Creutzfeldt–Jakob disease MM1 (methionine homozygote, prion protein type 1) (lanes 1, 2, and 4), variant Creutzfeldt–Jakob 
dis ease (lane 3), and healthy controls (lanes 5, 6, and 7) were processed. Fractions corresponding to debris and supernatant were collected 
for each sample and subjected to serial rounds of 96 PMCA cycles. As a positive control, a urine specimen obtained from a healthy person 
(lane 9) was supplemented with a 10−5 dilution of variant Creutzfeldt–Jakob disease brain homogenate. Lane 8 shows the molecular-weight 
marker, and lane 10 shows the normal brain homogenate, which was not treated with proteinase K (used as an electrophoretic migration 
marker). The result with the urine sample from one patient with variant Creutzfeldt–Jakob disease was representative of the 13 samples 
with positive test results. As shown in Panel C, urine samples obtained from patients who had other neurodegenerative disorders, including 
Alzheimer’s disease (lane 1), frontotemporal dementia (lanes 2 and 4), Parkinson’s disease (lane 3), and progressive supranuclear palsy 
(lane 5) were subjected to seven serial rounds of PMCA. The results for rounds 1, 3, 5, and 7 are shown, as well as the results with no amplifi-
cation. Lane 6 shows a urine sample from a healthy control, lane 7 shows the molecular-weight marker, and lane 9 shows the normal brain 
homogenate not treated by proteinase K. Lane 8 shows samples of urine from a healthy control supplemented with a 10−5 dilution of variant 
Creutzfeldt–Jakob disease brain homogenate. All samples were treated with proteinase K, except the NBH used as a PrPC migration control.
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retic characteristics of PrPSc in urine were the 
same in all the patients with variant Creutzfeldt–
Jakob disease, regardless of their country of ori-
gin, and corresponded to the typical electro-
phoretic features of variant Creutzfeldt–Jakob 
disease (i.e., a type 2B mobility with predomi-
nance of the diglycosylated isoform) (Fig. 3A). 
All tests were repeated twice, and we never de-
tected a false positive result in any of the 224 
samples obtained either from patients with 
other diseases or healthy controls. To study 
whether PrPSc is detectable in the urine of pa-
tients with variant Creutzfeldt–Jakob disease at 
different times during the clinical phase of the 
disease, urine obtained at two distinct times 
from a single patient with variant Creutzfeldt–
Jakob disease (vCJD, Patient 2 in Fig. 3A, and in 
Table S1 in the Supplementary Appendix) was 
analyzed by means of PMCA. As shown in 
Figure 3C, the 2 samples from this patient, col-
lected 117 days apart, were both positive for 
PrPSc, with similar characteristics. However, the 
sample obtained later in the course of the clini-
cal disease appeared to have a larger quantity of 
PrPSc, since it required one less PMCA round for 
detection (Fig. 3C).
concentration of prpSc in urine from patients 
with variant creutzfeldt–jakob disease
To estimate the concentration of PrPSc in urine 
from patients with variant Creutzfeldt–Jakob dis-
ease, we used the quantitative PMCA procedure, 
as previously described.27 First, we estimated the 
concentration of PrPSc in the variant Creutzfeldt–
Jakob disease brain homogenate used to cali-
brate PMCA. The estimation was based on a com-
parison of the PrPSc signal by means of Western 
blot analysis with a known concentration of re-
combinant prion protein (Fig. S2A in the 
Supplementary Appendix). Using this procedure, 
we calculated that the PrPSc concentration in the 
brain of this patient was approximately 100 μg 
per gram.
Thereafter, we supplemented urine from a 
healthy control with different concentrations of 
this brain homogenate and used these samples 
for PrPSc detection (Fig. S2B in the Supplemen-
tary Appendix). One round of PMCA enabled us 
to detect approximately 10−12 to 10−13 g of PrPSc 
per milliliter in urine. Two rounds of PMCA per-
mitted detection of 10−15 to 10−16 g per milliliter, 
and three or more rounds of PMCA consistently 
detected 10−16 g per milliliter of PrPSc (Fig. S2B 
in the Supplementary Appendix), which is the 
last detectable quantity. Of the 13 urine samples 
obtained from patients with variant Creutzfeldt–
Jakob disease in which PrPSc was detectable by 
means of PMCA, 1 was positive in the first 
round, 6 were positive in the second round, 3 in 
the third round, and 3 in the fourth round. There-
fore, on average, PrPSc was detectable in urine in 
approximately 2.5 rounds of PMCA. Accordingly, 
our estimation is that the urine of patients with 
variant Creutzfeldt–Jakob disease contains a PrPSc 
concentration of approximately 1×10−16 g per 
milliliter, or 3×10−21 mol per milliliter (assuming 
the molecular weight of the monomer). This 
finding extrapolates to a concentration of ap-
proximately 2000 molecules of prion protein 
monomer per milliliter of urine. Since most es-
timations for the average size of the infectious 
PrPSc particle indicate that it contains between 
Table 1. Urine Samples That Were Positive for PrPSc Detection by PMCA, According to Study Group.*
Group
Urine Samples in Which  
PrPSc Was Detected
no./total no.
Patients with variant Creutzfeldt–Jakob disease 13/14
Patients with sporadic Creutzfeldt–Jakob disease  0/68
Patients with genetic prion disease (familial Creutzfeldt–Jakob disease or Gerstmann–
Sträussler–Scheinker syndrome)
0/4
Patients with other degenerative neurologic diseases  0/50
Patients with nondegenerative neurologic diseases  0/50
Healthy controls  0/52
* PMCA denotes protein misfolding cyclic amplification, and PrPSc misfolded prion protein.
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Figure 3. PrPSc Detection in Urine Samples Obtained from Patients with Variant Creutzfeldt–Jakob Disease.
Urine samples obtained from 14 patients with variant Creutzfeldt–Jakob disease (vCJD) were used to detect PrPSc by 
means of PMCA. Panel A shows the results obtained with the use of the supernatant fraction after three rounds of 
PMCA for four urine samples obtained from patients with vCJD, as well as samples obtained from persons with 
other neurodegenerative diseases and healthy controls (HC) (left). The dotted line indicates blot splicing. To com-
pare the electrophoretic migration, aliquots of brain homogenate from patients with vCJD and patients with spo-
radic Creutzfeldt–Jakob disease MM1 (sCJD) were run in the same gel. Results obtained with the supernatant frac-
tion of various nonvariant Creutzfeldt–Jakob disease urine samples (third round of PMCA) are shown on the right. 
NBH corresponds to the aliquots of brain homogenate from transgenic mice expressing human prion protein with-
out proteinase K treatment, which were used as a migration control for PrPC electrophoretic mobility. AD denotes 
Alzheimer’s disease, fCJD familial Creutzfeldt–Jakob disease, FTD frontotemporal dementia, GSS Gerstmann–
Sträussler–Scheinker syndrome, PD Parkinson’s disease, and PSP progressive supranuclear palsy. As shown in 
Panel B, to determine whether PrPSc can be detected in larger volumes of urine in samples obtained from patients 
with nonvariant Creutzfeldt–Jakob disease, 10 ml of urine from 10 different patients with other neurologic diseases 
(ND), 10 patients with sCJD, and 10 healthy persons were processed without separating debris from supernatant. 
The entire content pelleted from the 10 ml was used for PMCA. The results obtained after four rounds of PMCA for 
urine samples obtained from 8 of the 10 persons in each group are shown. NBH refers to the normal brain homog-
enate not treated with proteinase K, which was used as a migration control. As shown in Panel C, urine samples  
(1 ml) obtained at two different times from the same patient (vCJD, Patient 2) were subjected to PMCA detection. 
The data in parentheses refer to the dates on which urine samples were obtained. The results obtained after three 
or four rounds of PMCA are shown. Control samples obtained from patients with Alzheimer’s disease (AD), patients 
with Parkinson’s disease (PD), and healthy persons were run simultaneously. The asterisks indicate faint signals 
from incomplete PrPC digestion.
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20 and 50 monomers of prion protein,28,29 we 
conclude that 1 ml of urine obtained from a 
patient with variant Creutzfeldt–Jakob disease 
has between 40 and 100 oligomer equivalents 
of PrPSc.
Discussion
We found that small quantities of PrPSc are ex-
creted into the urine of most patients with vari-
ant Creutzfeldt–Jakob disease. The one patient 
(Patient 8 in Table S1 in the Supplementary 
Appendix) with a urine sample that was found to 
be negative had a disease duration of 114 months 
and was receiving treatment with intracerebro-
ventricular administration of pentosan polysul-
fate, an agent that has been studied for the treat-
ment of variant Creutzfeldt–Jakob disease.30 
Another patient with variant Creutzfeldt–Jakob 
disease (Patient 10), whose urine was positive for 
PrPSc, was receiving similar treatment; however, 
this patient had disease with a duration of 16 
months (Table S1 in the Supplementary Ap-
pendix).
PrPSc was detectable only after extensive am-
plification by means of PMCA, suggesting that 
the concentration of the infectious protein in 
urine is small. Estimations by means of quanti-
tative PMCA suggest that 1 ml of urine obtained 
from a patient with variant Creutzfeldt–Jakob 
disease contains as little as 40 to 100 oligo-
meric PrPSc particles. The results also indicate 
that urinary PrPSc has the ability to self-propa-
gate in vitro by inducing the misfolding of nor-
mal human PrP C. PrPSc was not detectable in any 
of the urine samples obtained from patients who 
had other human transmissible spongiform en-
cephalopathies, suggesting that it is an exclusive 
feature of variant Creutzfeldt–Jakob disease. This 
result is not entirely surprising, considering that 
variant Creutzfeldt–Jakob disease is acquired by 
infection (probably by oral ingestion), and stud-
ies have shown more extensive peripheral involve-
ment in variant Creutzfeldt–Jakob disease than 
in the sporadic or inherited forms of transmis-
sible spongiform encephalopathies.5,31,32 Indeed, 
PrPSc is readily detectable by means of immuno-
histochemical or biochemical studies in lymph 
nodes, tonsil, spleen, portions of the intestinal 
tract, kidney, liver, pancreas, and skeletal muscle 
from patients with variant Creutzfeldt–Jakob 
disease.5,32-34
In conclusion, the results of our study show 
that PrPSc can be detected in the urine of patients 
with variant Creutzfeldt–Jakob disease with high 
sensitivity and specificity. Further studies are 
needed to determine whether the detection of 
PrPSc in urine can be used diagnostically.
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Table 2. Estimated Sensitivity, Specificity, and Predictive Value of PMCA for PrPSc Detection in Urine from Patients  
with Variant Creutzfeldt–Jakob Disease.*
Groups Sensitivity Specificity
Positive 
Predictive 
Value
Negative 
Predictive 
Value
% (95% CI) %
Variant Creutzfeldt–Jakob disease vs. other 
transmissible spongiform encephalopathies
92.9 (66.1–99.8) 100 (95–100) 100 98.3
Variant Creutzfeldt–Jakob disease vs. other 
neurologic diseases
92.9 (66.1–99.8)   100 (96.4–100) 100 99.0
Variant Creutzfeldt–Jakob disease vs. all† 92.9 (66.1–99.8)   100 (98.4–100) 100 99.6
* Estimates of sensitivity and specificity, with 95% confidence intervals (CI), and predictive values were calculated with 
the use of MedCalc software according to the following formulas: sensitivity = [true positive results ÷ (true positive 
 results + false negative results)] × 100; specificity = [true negative results ÷ (false positive results + true negative results)] 
 × 100; positive predictive value = [true positive results ÷ (true positive results + false positive results)] × 100; and negative 
predictive value = [true negative results ÷ (true negative results + false negative results)] × 100.
† All refers to all samples that were not obtained from patients with variant Creutzfeldt–Jakob disease (i.e., patients with 
sporadic Creutzfeldt–Jakob disease, familial transmissible spongiform encephalopathies, or other neurologic diseases 
[including other degenerative neurologic diseases and nondegenerative neurologic disorders] and healthy controls).
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